Compare CRSP & IFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | IFS |
|---|---|---|
| Founded | 2013 | 1897 |
| Country | Switzerland | Peru |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 6.4B |
| IPO Year | 2016 | 2014 |
| Metric | CRSP | IFS |
|---|---|---|
| Price | $53.74 | $55.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $70.29 | $48.00 |
| AVG Volume (30 Days) | ★ 1.6M | 384.2K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | N/A |
| Revenue Next Year | $172.52 | $7.38 |
| P/E Ratio | ★ N/A | $9.61 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $35.45 |
| 52 Week High | $78.48 | $58.16 |
| Indicator | CRSP | IFS |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 60.63 |
| Support Level | $50.17 | $43.65 |
| Resistance Level | $60.10 | $58.16 |
| Average True Range (ATR) | 2.57 | 2.04 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 60.16 | 79.95 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services, and payments for retail customers and commercial clients in Peru. Its purpose is centered around building financial well-being together. The company has three operating business segments: Banking, mainly loans, credit facilities, deposits, and current accounts; Insurance provides life annuity products with single-premium payment and conventional life insurance products, as well as other retail insurance products; and Wealth management provides brokerage and investment management services. Inteligo serves mainly Peruvian citizens.